A placebo-controlled trial of the insulin-sensitizing PPAR-gamma agonist rosiglitazone in patients with AD

被引：0
|
作者：
Craft, S [1 ]
Watson, GS [1 ]
Asthana, S [1 ]
Chapman, D [1 ]
Reger, M [1 ]
Baker, LD [1 ]
Hyde, K [1 ]
Cholerton, B [1 ]
Plymate, S [1 ]
Kahn, S [1 ]
机构：
[1] Univ Washington, VAPSHCS, Seattle, WA 98195 USA
来源：
NEUROBIOLOGY OF AGING | 2002年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
344
引用
收藏
页码：S91 / S91
页数：1
相关论文
共 50 条
  • [1] Treatment with the insulin-sensitizing PPAR-? agonist rosiglitazone preserves cognition and modulates plasma a-amyloid in patients with AD and amnestic MCI
    Craft, S
    Watson, GS
    Baker, L
    Cholerton, B
    Reger, M
    Plymate, S
    Fishel, M
    Kahn, S
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 104 - 104
  • [2] A double blind randomised placebo controlled trial of the PPAR-gamma agonist pioglitazone in mild asthma
    Anderson, John
    Mortimer, Kevin
    Pang, Linhua
    Smith, Katherine
    Baileyh, Helen
    Knox, Alan
    Harrison, Tim
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [3] Ragaglitazar:: a novel PPARα & PPARδ agonist with potent lipidlowering and insulin-sensitizing efficacy in animal models
    Chakrabarti, R
    Vikramadithyan, RK
    Misra, P
    Hiriyan, J
    Raichur, S
    Damarla, RK
    Gershome, C
    Suresh, J
    Rajagopalan, R
    BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (03) : 527 - 537
  • [4] PPAR-GAMMA AGONIST ROSIGLITAZONE ALLEVIATES THE FIBROTIC PHENOTYPE OF SKIN SCLERODERMA FIBROBLASTS
    Kapoor, Mohit
    Shi-Wen, Xu
    Denton, Christopher P.
    Abraham, David J.
    Leask, Andrew
    WOUND REPAIR AND REGENERATION, 2009, 17 (04) : A70 - A70
  • [5] A randomized, placebo-controlled trial of the PPARγ ligand rosiglitazone for active ulcerative colitis
    Lewis, J. D.
    Lichtenstein, G. R.
    Deren, J. J.
    Chuai, S.
    Ellenberg, J. H.
    Nessel, L.
    Wu, G. D.
    Sands, B. E.
    Hanauer, S. B.
    Katz, J. A.
    Lashne, B.
    Present, D. H.
    GASTROENTEROLOGY, 2007, 132 (07) : 2585 - 2585
  • [6] PPAR-Gamma agonist rosiglitazone is neuroprotective after stroke in type II diabetic rodents
    Vemuganti, R.
    Tureyen, K.
    Satriotomo, I.
    Bowen, K.
    Kapadia, R.
    Feinstein, D.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2009, 29 : S253 - S253
  • [7] PPAR-Gamma Agonist Rosiglitazone Attenuates the Inflammation Caused by Carrageenan in the Mouse Model of Pleurisy
    Ziliani da Silva Buss
    Yara S. Medeiros
    Tania S. Fröde
    Inflammation, 2012, 35 : 280 - 288
  • [8] PPAR-Gamma Agonist Rosiglitazone Attenuates the Inflammation Caused by Carrageenan in the Mouse Model of Pleurisy
    Buss, Ziliani da Silva
    Medeiros, Yara S.
    Froede, Tania S.
    INFLAMMATION, 2012, 35 (01) : 280 - 288
  • [9] The PPAR-gamma agonist rosiglitazone reduces endothelial activation in non-diabetic coronary artery disease patients
    Sidhu, JS
    Cowan, D
    Kaski, JC
    EUROPEAN HEART JOURNAL, 2002, 23 : 492 - 492
  • [10] The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: A placebo-controlled randomized clinical trial
    Caballero, AE
    Saouaf, R
    Lim, SC
    Hamdy, O
    Abou-Elenin, K
    O'Connor, C
    LoGerfo, FW
    Horton, ES
    Veves, A
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (02): : 173 - 180
12345